Table 2. Distribution of aberrant patterns of antigen expression on bone marrow maturing and mature neutrophils from pediatric BCP-ALL patients studied at diagnosis: relationship with the genetic subtype of the disease.
| Immunophenotypic marker | MLL rearrangement (n = 11) | Hyperdiploidy (n = 34) | t (12;21) (n = 21) | t (1;19) (n = 5) | Rare (n = 8) | Normal karyotype (n = 28) | Total (n = 107)* | p-Value |
|---|---|---|---|---|---|---|---|---|
| CD10 |
27% (3/11§) |
53% (18/34) |
67% (14/21) |
80% (4/5) |
63% (5/8) |
50% (14/28) |
58% (62/107) |
ns |
| CD33 |
9.1% (1/11§) |
31% (9/29) |
45% (9/20) |
20% (1/5) |
25% (2/8) |
42% (10/24) |
33% (32/97) |
ns |
| CD13 |
18% (2/11) |
19% (6/31) |
15% (3/20) |
20% (1/5) |
38% (3/8) |
7% (2/27) |
17% (17/102) |
ns |
| CD123 |
9.1% (1/11) |
6% (2/32) |
17% (3/18) |
20% (1/5) |
25% (2/8) |
7% (2/28) |
8.8% (10/114) |
ns |
| CD15/CD65 |
18% (2/11) |
9% (3/32) |
16% (3/19) |
20% (1/5) |
13% (1/8) |
4% (1/26) |
11% (11/101) |
ns |
| ≥ 1 altered phenotypic marker |
73% (8/11) |
77% (24/31) |
85% (17/20) |
100% (5/5) |
75% (6/8) |
76% (19/25) |
79% (79/100) |
ns |
The denominator in each fraction is the total number of patients with the genetic alteration evaluated for each specific marker.
*
The total of patients was 107 because there were 11 cases with missing data concerning genetic alterations.
§
p-value < 0.05, vs. patients without MLL gene rearrangements.